



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	99995	Guo Min Bi Yan Fang a.k.a. Xanthium & Astragalus Chronic Sinus Formula
ARTG entry for	Medicine Listed	
Sponsor	Sun Herbal Pty Ltd	
Postal Address	Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208 Australia	
ARTG Start Date	3/03/2004	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Guo Min Bi Yan Fang a.k.a. Xanthium & Astragalus Chronic Sinus Formula

Product Type	Effective Date
Single Medicine Product	12/04/2018

Permitted Indications

- Traditionally used in Chinese medicine to clear/dry/drain/eliminate/resolve dampness
- Traditionally used in Chinese medicine to stabilise Exterior
- Traditionally used in Chinese medicine to engender Fluid
- Traditionally used in Chinese medicine to dispel/expel/disperse/clear external/exogenous heat
- Traditionally used in Chinese medicine to tonify/nourish/strengthen/replenish Qi
- Traditionally used in Chinese medicine to tonify/nourish/strengthen/replenish/fortify/invigorate spleen
- Traditionally used in Chinese medicine to enrich/nourish/tonify/fortify/strengthen kidneys
- Traditionally used in Chinese medicine to dispel/expel/extinguish/disperse/clear exogenous wind
- Traditionally used in Chinese medicine to calm/soothe/nourish the liver
- Traditionally used in Chinese medicine to unblock/clear nasal passages

Indication Requirements

- If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.
- Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.
- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to kidney disease.
- Product presentation must not imply or refer to disease in any body organ.

Standard Indications

No Standard Indications included on Record



Australian Government
Department of Health
Therapeutic Goods Administration

Specific Indications

No Specific Indications included on Record

Warnings

For practitioner dispensing only.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Angelica dahurica root Extract dry concentrate	20.4 mg
Equivalent: Angelica dahurica (Dry)	122.4 mg
Astragalus membranaceus root Extract dry concentrate	27 mg
Equivalent: Astragalus membranaceus (Dry)	162 mg
Atractylodes lancea rhizome Extract dry concentrate	19.8 mg
Equivalent: Atractylodes lancea (Dry)	118.8 mg
Atractylodes macrocephala rhizome Extract dry concentrate	22.5 mg
Equivalent: Atractylodes macrocephala (Dry)	135 mg
Ledebouriella seseloides root Extract dry concentrate	20.4 mg
Equivalent: Ledebouriella seseloides (Dry)	122.4 mg
Lycium chinense fruit Extract dry concentrate	22.5 mg
Equivalent: Lycium chinense (Dry)	135 mg
Magnolia liliflora flower bud Extract dry concentrate	20.4 mg
Equivalent: Magnolia liliflora (Dry)	122.4 mg
Mentha haplocalyx leaf Extract dry concentrate	20.4 mg
Equivalent: Mentha haplocalyx (Dry)	122.4 mg
Morus alba fruit Extract dry concentrate	22.5 mg
Equivalent: Morus alba (Dry)	135 mg
Pseudostellaria heterophylla root Extract dry concentrate	20.4 mg
Equivalent: Pseudostellaria heterophylla (Dry)	122.4 mg
Pueraria lobata root Extract dry concentrate	20.4 mg
Equivalent: Pueraria lobata (Dry)	122.4 mg
Rehmannia glutinosa root Extract dry concentrate	22.5 mg
Equivalent: Rehmannia glutinosa (Dry)	135 mg
Scutellaria baicalensis root Extract dry concentrate	20.4 mg
Equivalent: Scutellaria baicalensis (Dry)	122.4 mg
Xanthium sibiricum fruit Extract dry concentrate	20.4 mg
Equivalent: Xanthium sibiricum (Dry)	122.4 mg

Other Ingredients (Excipients)

hydrolysed gelatin

titanium dioxide

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary